Hospital Injectable Products · LP-174
Adrenaline Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-174Hospital Injectable Products
- Generic identity
- AdrenalineInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-174
- Generic ingredient
- Adrenaline
- Dosage form
- Injection
- Proposed strength
- 1 mg/mL
- Proposed pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
About Adrenaline
Adrenaline, called epinephrine in many references, is an adrenergic medicine with important emergency uses. It affects the heart, blood vessels and airways. Its role in anaphylaxis is distinct from uses in resuscitation or monitored critical care. Concentration, route and clinical context are crucial, and a hospital ampoule must not be confused with an autoinjector intended for a prescribed emergency plan.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Anaphylaxis requires immediate emergency management, while other adrenaline uses are governed by resuscitation or critical-care protocols. The same ingredient can be supplied in different concentrations and devices with very different instructions. This catalogue does not supply a dilution method, injection technique or resuscitation regimen. It describes an ampoule candidate and points to ingredient-level reference material, whose device-specific instructions cannot be transferred to that ampoule.
Important safety considerations
Tachycardia, palpitations, tremor, anxiety and hypertension can occur. Serious arrhythmia, myocardial ischaemia and tissue injury from incorrect administration are possible. A concentration or route error can be life-threatening. Relevant cardiovascular conditions and interacting medicines require assessment, while emergency treatment decisions follow the actual clinical situation. Accidental injection or severe cardiovascular symptoms need urgent evaluation. Local policies should explicitly address ampoule identification and high-alert medicine handling.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The record describes a 1 mg/mL ampoule. It does not describe an autoinjector or an automatically ready-to-use preparation for every route. Exact adrenaline salt, strength-expression convention, excipients and authorized routes must be verified.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the emergency or critical-care indication, concentration, route and locally approved protocol. Independently check the product and ensure appropriate trained personnel and monitoring.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Adrenaline
- Dosage form / presentation
- Injection
- Catalogue strength
- 1 mg/mL
- Catalogue pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue establishes adrenaline injection at 1 mg/mL in a 1 mL ampoule. It does not identify the exact salt, authorised route, dilution, compatibility or ready-to-use status.
- An ampoule is not an autoinjector. External epinephrine device or vial instructions do not define this catalogue presentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Epinephrine Injection — adrenaline contextgovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-174, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-174.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.